SANDOZ ADAPALENE / BENZOYL PEROXIDE GEL

Država: Kanada

Jezik: engleski

Izvor: Health Canada

Kupi sada

Preuzimanje Svojstava lijeka (SPC)
05-09-2019

Aktivni sastojci:

ADAPALENE; BENZOYL PEROXIDE

Dostupno od:

SANDOZ CANADA INCORPORATED

ATC koda:

D10AD53

INN (International ime):

ADAPALENE, COMBINATIONS

Doziranje:

0.1%; 2.5%

Farmaceutski oblik:

GEL

Sastav:

ADAPALENE 0.1%; BENZOYL PEROXIDE 2.5%

Administracija rute:

TOPICAL

Jedinice u paketu:

15G/50G

Tip recepta:

Prescription

Područje terapije:

KERATOLYTIC AGENTS

Proizvod sažetak:

Active ingredient group (AIG) number: 0252888001; AHFS:

Status autorizacije:

APPROVED

Datum autorizacije:

2019-09-09

Svojstava lijeka

                                _SANDOZ ADAPALENE/BENZOYL PEROXIDE Product Monograph _
_Page 1 of 41_
PRODUCT MONOGRAPH
Pr
SANDOZ ADAPALENE/BENZOYL PEROXIDE
adapalene and benzoyl peroxide topical gel, 0.1%/2.5% w/w
Acne Therapy
SANDOZ CANADA INC.
110 rue de Lauzon
Boucherville, Québec J4B1E6
Date of Preparation:
September 5, 2019
Submission Control No: 230590
_SANDOZ ADAPALENE/BENZOYL PEROXIDE Product Monograph _
_Page 2 of 41_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
..................................................................................................12
DOSAGE AND ADMINISTRATION
..............................................................................13
OVERDOSAGE
................................................................................................................13
ACTION AND CLINICAL PHARMACOLOGY
............................................................14
STORAGE AND STABILITY
..........................................................................................17
SPECIAL HANDLING INSTRUCTIONS
.......................................................................17
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................17
PART II: SCIENTIFIC INFORMATION
................................................................................18
PHARMACEUTICAL INFORMATION
.........................................................................
                                
                                Pročitajte cijeli dokument
                                
                            

Dokumenti na drugim jezicima

Svojstava lijeka Svojstava lijeka francuski 05-09-2019